Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"Prebiotic oligosaccharides mixture II" refers to a specific formulation developed by Danone/Nutricia, consisting of a proprietary blend of short-chain galacto-oligosaccharides (scGOS) and long-chain fructo-oligosaccharides (lcFOS) in a 9:1 ratio. This mixture is designed to mimic the diversity and function of oligosaccharides found in human breast milk. [7, 8, 9] As a prebiotic, it is not digested in the upper gastrointestinal tract and reaches the colon, where it serves as a substrate for beneficial gut bacteria, selectively stimulating the growth of species like *Bifidobacteria* and *Lactobacilli*. [8] It is primarily used as a key ingredient in infant formulas to support the development of a healthy gut microbiome, which is associated with improved stool characteristics and beneficial effects on the immune system. [8, 9] The specific term "prebiotic oligosaccharides mixture II" was used to identify this intervention in a clinical trial (NCT01507935) sponsored by Danone to study its effects on gut microbiota in healthy infants. [1, 12]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prebiotic oligosaccharides mixture II.